Evofem Biosciences

EVFMPhase 3

Evofem Biosciences is dedicated to addressing critical unmet needs in women's healthcare through innovative, hormone-free products. The company successfully launched Phexxi®, a first-in-class vaginal pH modulator for on-demand contraception, and acquired Solosec®, a single-dose oral antibiotic for bacterial vaginosis. With a growing commercial footprint and a pipeline exploring new indications, Evofem is targeting a multi-billion dollar market opportunity in contraception and sexual health.

Market Cap

$1.1M

-11.1% period

Pipeline

6 in Phase 3

Patents

—

Publications

—

EVFM · Stock Price

USD 0.010.00 (-11.11%)

Historical price data

AI Company Overview

Women's HealthContraceptionInfectious DiseaseSexual Health

Technology Platform

Proprietary vaginal pH modulator technology designed to maintain an acidic environment, immobilizing sperm for contraception and potentially inhibiting pathogens for other indications.

Pipeline

7 drugs in pipeline6 in Phase 3

Drug	Indication	Stage
LIPO-202 + Placebo	Central Abdominal Bulging	Phase 3
LIPO-202 + Placebo	Central Abdominal Bulging	Phase 3
AMPHORA	Contraception	Phase 3
Conceptrol + Amphora	Contraception	Phase 3
EVO100 + Placebo	Sexually Transmitted Diseases	Phase 3

Funding History

Total raised:$150M

Debt$50MPerceptive AdvisorsMay 15, 2021

IPO$75MUndisclosedOct 11, 2018

Series D$25MUndisclosedSep 15, 2017

Opportunities

Significant growth opportunity lies in capturing market share from the 23M+ U.S.

women not using hormonal contraception with Phexxi®.

Expansion into international markets (e.g., UAE/GCC) and the development of a multipurpose prevention product for HIV could open new, substantial revenue streams and address critical global health needs.

Risk Factors

Key risks include commercial execution challenges in a competitive contraceptive market, the company's current lack of profitability and reliance on capital markets, and the uncertainty of clinical success for early-stage pipeline candidates like EVO200 and the HIV MPT.

Competitive Landscape

Phexxi® faces competition from a wide array of hormonal contraceptives (pills, IUDs, implants) but is differentiated as the only FDA-approved, hormone-free, on-demand prescription option. Solosec® competes with other antibiotics for BV but offers a convenient single-dose regimen. Its pipeline targets areas with limited innovation, such as recurrent BV prevention.